Pre-made Petosemtamab benchmark antibody ( Bispecific mAb, anti-EGFR;LGR5 therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;FEX/GPR49/GPR67/GRP49/HG38 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-440

Pre-Made Petosemtamab biosimilar, Bispecific mAb, Anti-EGFR;LGR5 Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;FEX/GPR49/GPR67/GRP49/HG38 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Petosemtamab (also known as MCLA 158) is a bispecific, full length human IgG antibody being developed by Merus, for the treatment of solid tumours including.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-440-1mg 1mg Inquiry
GMP-Bios-ab-440-10mg 10mg Inquiry
GMP-Bios-ab-440-100mg 100mg Inquiry
GMP-Bios-ab-440-xmg ＞100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Petosemtamab biosimilar, Bispecific mAb, Anti-EGFR;LGR5 Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;FEX/GPR49/GPR67/GRP49/HG38 therapeutic antibody
INN Name Petosemtamab
TargetEGFR;LGR5
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2019
Year Recommended2020
CompaniesMerus
Conditions Approvedna
Conditions Activena
Conditions Discontinuedna
Development Techna